scispace - formally typeset
M

Michael B. Sporn

Researcher at Dartmouth College

Publications -  561
Citations -  96644

Michael B. Sporn is an academic researcher from Dartmouth College. The author has contributed to research in topics: Transforming growth factor & Transforming growth factor beta. The author has an hindex of 157, co-authored 559 publications receiving 94605 citations. Previous affiliations of Michael B. Sporn include Cornell University & Reata Pharmaceuticals.

Papers
More filters
Journal Article

Antagonistic Actions of Retinoic Acid and Dexamethasone on Anchorage-independent Growth and Epidermal Growth Factor Binding of Normal Rat Kidney Cells

Anita B. Roberts, +4 more
- 01 Apr 1984 - 
TL;DR: The abilities of retinoic acid and dexamethasone to alter expression of the transformed phenotype induced by treatment of normal rat kidney cells with TGF-beta and EGF are mediated at least in part through their effects on the EGF receptor.
Journal ArticleDOI

Antibodies to transforming growth factor-β2 peptides: Specific detection of TGF-β2 in immunoassays

Kathleen C. Flanders, +5 more
- 01 Jan 1990 - 
TL;DR: None of the TGF-β2 peptide antibodies was able to block receptor binding of either TGF -β1 or 2, and both anti-P 50–75(2) andAnti-P 79–108 (2) specifically immunoprecipitated TGF,β2 under reducing conditions only.
Patent

Therapeutic compounds and methods of use

Gribble Gordon W, +3 more
TL;DR: In this article, the authors present a list of compounds and methods useful for chemopreventive treatment of diseases such as cancer, Alzheimer's disease, Parkinson disease, inflammatory bowel diseases and multiple sclerosis.
Journal ArticleDOI

Aberrant TGF-β Production and Regulation in Metastatic Malignancy

Lois C. Schwarz, +7 more
- 01 Jan 1990 - 
TL;DR: Despite the greatly enhanced rate of secretion of activated T GF-β, metastatic cells exhibited markedly altered responses of TGF-β1, and TGF -β2., being unable to either increase collagen sec...
Journal ArticleDOI

Triterpenoids CDDO-Methyl Ester or CDDO-Ethyl Amide and Rexinoids LG100268 or NRX194204 for Prevention and Treatment of Lung Cancer in Mice

Karen T. Liby, +6 more
- 01 Dec 2009 - 
TL;DR: It is shown for the first time that these drugs also were highly effective for treatment of experimental lung cancer, and all triterpenoid and rexinoid combinations reduced ATB 85% to 87% compared with the control group.